Interactive Features

Quiz

Combination Iadademstat and Azacitidine for Patients With Patients With Newly Diagnosed AML

09/25/2024

True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...

True or False: According to...

09/25/2024

Oncology

Quiz

Treating Acute Myeloid Leukemia With Aspacytarabine

03/05/2024

True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.

True or False: Aspacytarabine...

03/05/2024

Oncology

Quiz

Fractionated Vs Single-Dose Gemtuzumab Ozogamicin Among Older Patients With AML

02/15/2024

True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...

True or False: Fractionated...

02/15/2024

Oncology

Quiz

Humanized Bispecific Antibody Vibecotamab for R/R AML

02/07/2024

True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.

True or False: Administering...

02/07/2024

Oncology

Quiz

Treating TP53-Mutated AML With Venetoclax Plus HMA Therapy

01/10/2024

True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...

True or False: According to...

01/10/2024

Oncology

Quiz

Fludarabine-Based Regimen Vs Standard 7 + 3 Regimen for WT1-Mutated AML

12/09/2023

A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...

A fludarabine-based regimen did...

12/09/2023

Oncology

Quiz

Sorafenib Maintenence After AlloHSCT For FLT3-ITD-Mutated AML

12/04/2023

True or False: Results from a post-hoc analysis from a phase 3 trial indicated that sorafenib maintenance after allogeneic hematopoietic stem-cell transplantation (alloHSCT) was effective among patients with FLT3 internal tandem duplication...

True or False: Results from a...

12/04/2023

Oncology

Quiz

Azacitidine, Venetoclax, and Pevonedistat Combination for Secondary AML, MDS, or CMML

11/09/2023

True or False: The triplet combination of azacitidine, venetoclax, and pevonedistat yielded encouraging responses among patients with newly diagnosed secondary AML, MDS, or CMML.

True or False: The triplet...

11/09/2023

Oncology

Quiz

Treating AML With Gemtuzumab Ozogamicin Plus Intensive Chemotherapy

09/26/2023

True or False: Findings from a phase 3 trial indicate that the addition of anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin to intensive chemotherapy demonstrated promising efficacy among patients with newly diagnosed NPM1-mutated AML.

True or False: Findings from a...

09/26/2023

Oncology

Quiz

Treating R/R AML With Venetoclax, Azacitidine, and Homoharringtonine

09/11/2023

According to a phase 2 trial, the combination of venetoclax, azacitidine, and homoharringtonine demonstrated _____ among patients with relapsed/refractory acute myeloid leukemia.

According to a phase 2 trial,...

09/11/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology